Our Team

We are led by an accomplished team with an exceptional track record of discovering, developing and commercializing meaningful therapies for patients while creating value for stockholders. Our founding team has deep knowledge and significant experience in cGMP pathway research and development.

Andy Busch, PhD

Chief Innovation Officer

Mark Currie, PhD

President and Chief Scientific Officer

Christopher Wright, MD, PhD

Chief Medical Officer

Cheryl Gault

Head of Strategy

Mark Gaffney

Head of External Innovation and Corporate Development

Craig Dunbar, PhD

Vice President, Pharmaceutical Development

Mary Christian, PharmD, MBA

Vice President, Global Quality, Regulatory, and Safety

Peter Hecht, PhD

Chief Executive Officer

Daryn Lewis

Head of People

William Huyett

Chief Financial Officer

Brian Cali, PhD

Head of Investor Relations and Corporate Communications

Anjeza Gjino

Vice President, Finance

Andy Busch, PhD

Chief Innovation Officer

Mark Currie, PhD

President and Chief Scientific Officer

Christopher Wright, MD, PhD

Chief Medical Officer

Cheryl Gault

Head of Strategy

Mark Gaffney

Head of External Innovation and Corporate Development

Craig Dunbar, PhD

Vice President, Pharmaceutical Development

Mary Christian, PharmD, MBA

Vice President, Global Quality, Regulatory, and Safety

Peter Hecht, PhD

Chief Executive Officer

Daryn Lewis

Head of People

William Huyett

Chief Financial Officer

Brian Cali, PhD

Head of Investor Relations and Corporate Communications

Anjeza Gjino

Vice President, Finance

A Novel Leadership Model to Drive Innovation

We have created a novel leadership model to efficiently advance a robust pipeline of sGC stimulators. The traditional pharmaceutical model often has research, development, customer insights and external innovation working separately and in silos. We are taking a different approach; our Innovation Center gathers our deep expertise in research, in development, in customer insights, and in external innovation together in one team, where we work together to optimize our drug candidates as we strive to make them into innovative products that address unmet medical needs in a complex commercial environment. This highly integrated approach, with an emphasis on shared ownership, is designed to overcome inefficiencies often inherent in drug research and development and help accelerate our goal to deliver meaningful medicines to patients and value to the healthcare system and our shareholders.

Our Innovation Center includes the traditional Research and Development functions and will also add Strategic Insights and External Innovation. The Research function is the heart of our innovation engine; this is where new drug candidates are invented and vetted for their likelihood to succeed in the clinic. The Development function brings deep expertise in clinical trial design and execution, regulatory strategy and pharmaceutical drug development in order to gather critical data on the clinical value of our investigational medicines. The Strategic Insights function is responsible for bringing the voices of patients, patient advocacy groups, payers and physicians to enhance our ability to create new medicines that will make a meaningful difference. The External Innovation function is responsible for engaging and managing our partnerships – both academic and industry partners – to maximize the value of our current pipeline and to build out our portfolio over time.

innovation-center

Board of Directors

Marsha Fanucci, Chair Peter Hecht, PhD Kevin Churchwell, MD George Conrades Ole Isacson, MD, PhD Stephanie Lovell Terrance McGuire Michael Mendelsohn, MD Amy Schulman
yellow-border

We are determined to create medicines that bring significant benefit to patients. We are committed to making a difference.

Top